As of 2026-06-10, the Relative Valuation of Chengdu Easton Biopharmaceuticals Co Ltd (688513.SS) is 44.59 CNY. This relative valuation is based on P/E multiples. With the latest stock price at 45.55 CNY, the upside of Chengdu Easton Biopharmaceuticals Co Ltd based on Relative Valuation is -2.1%.
The range of the Relative Valuation is 37.64 - 56.50 CNY.
| Range | Selected | |
| Trailing P/E multiples | 24.2x - 30.2x | 28.5x |
| Forward P/E multiples | 20.1x - 29.5x | 23.5x |
| Fair Price | 37.64 - 56.50 | 44.59 |
| Upside | -17.4% - 24.0% | -2.1% |
| Date | P/E |
| 2026-06-09 | 29.31 |
| 2026-06-08 | 29.37 |
| 2026-06-05 | 30.25 |
| 2026-06-04 | 30.16 |
| 2026-06-03 | 30.70 |
| 2026-06-02 | 30.04 |
| 2026-06-01 | 31.45 |
| 2026-05-29 | 34.16 |
| 2026-05-28 | 33.12 |
| 2026-05-27 | 33.02 |
| 2026-05-26 | 30.64 |
| 2026-05-25 | 31.86 |
| 2026-05-22 | 35.50 |
| 2026-05-21 | 35.86 |
| 2026-05-20 | 36.24 |
| 2026-05-19 | 36.26 |
| 2026-05-18 | 35.48 |
| 2026-05-15 | 37.32 |
| 2026-05-14 | 38.35 |
| 2026-05-13 | 40.75 |
| 2026-05-12 | 41.20 |
| 2026-05-11 | 41.62 |
| 2026-05-08 | 40.56 |
| 2026-05-07 | 40.51 |
| 2026-05-06 | 40.71 |
| 2026-04-30 | 41.43 |
| 2026-04-29 | 41.03 |
| 2026-04-28 | 41.20 |
| 2026-04-27 | 42.44 |
| 2026-04-24 | 40.97 |
| 2026-04-23 | 41.51 |
| 2026-04-22 | 42.99 |
| 2026-04-21 | 42.29 |
| 2026-04-20 | 42.56 |
| 2026-04-17 | 43.03 |
| 2026-04-16 | 42.42 |
| 2026-04-15 | 43.03 |
| 2026-04-14 | 42.84 |
| 2026-04-13 | 43.50 |
| 2026-04-10 | 43.69 |
| 2026-04-09 | 45.79 |
| 2026-04-08 | 47.46 |
| 2026-04-07 | 50.68 |
| 2026-04-03 | 51.22 |
| 2026-04-02 | 49.74 |
| 2026-04-01 | 47.09 |
| 2026-03-31 | 41.44 |
| 2026-03-30 | 42.70 |
| 2026-03-27 | 42.72 |
| 2026-03-26 | 39.90 |